The Future Of Microbiome Therapeutics

Report Code: BIO210A

|

October 2020

“Microbiome” refers to the trillions of microbes that inhabit the human body and live (mostly) in symbiosis with the human host. In the last two decades, information has shed light on the biological importance of human microbiome/microbiota, particularly on physiological, metabolic and immunological processes. Any disruption in the microbial population or host interaction leads to “dysbiosis.” This disruption of microbial diversity has now been associated with a multitude of chronic diseases and some infections.

BCC spoke with two microbiome experts: Sarah Daniels, PhD, from Thryve Inside, a company offering gut microbiome test kits and Dr. Ira Spector, CEO of SFA Therapeutics, a microbiome therapeutics company focused on treating chronic inflammatory diseases.

Continue reading this report plus more!

Monthly Access $9.99

  • Access to our Library of published and upcoming White Papers
  • Access to thousands of select free reports from publishers such as Barnes Reports, Datassential, TBRC, Verified Market Research, & Primary Research Group
  • Exclusive discounts on full length reports from BCC Research & various additional publishers
  • Cancel at anytime

Single Paper $59.99

  • One Time Purchase
  • Downloadable PDF